NASDAQ:SEPN

Septerna Q4 2024 Earnings Results & Report

Septerna logo
$41.67 -0.93 (-2.18%)
Closing price 04:00 PM Eastern
Extended Trading
$41.64 -0.02 (-0.06%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Septerna beat analyst expectations on both earnings and revenue in its Q4 2024 results, released March 27, 2025. The company reported EPS of -$0.64 versus the -$0.69 consensus estimate, while revenue of $210 thousand topped the $133 thousand estimate by $77.00 thousand.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Septerna EPS Results

Actual EPS
-$0.64
Consensus EPS
-$0.69
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Septerna Revenue Results

Actual Revenue
$210 thousand
Expected Revenue
$133 thousand
Beat/Miss
Beat by +$77.00 thousand
YoY Revenue Growth
N/A

Septerna Q4 2024 Earnings FAQ

Septerna (NASDAQ:SEPN) reported earnings of -$0.64 per share for Q4 2024, beating the consensus estimate of -$0.69. The report was announced on Thursday, March 27, 2025.

Septerna reported revenue of $210 thousand for Q4 2024, against a consensus estimate of $133 thousand.

Septerna Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
Septerna (NASDAQ:SEPN) Director Sells $3,934,723.80 in Stock
Septerna FY2026 Earnings Forecast Lowered by HC Wainwright
Septerna (NASDAQ:SEPN) Downgraded by Wall Street Zen to Sell
See More Septerna Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Septerna? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Septerna and other key companies, straight to your email.

About Septerna

Septerna (NASDAQ:SEPN) is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California.

Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Founded in 2021, Septerna has no marketed products; its work is focused on research and clinical development. The company has also pursued collaborations to apply its GPCR discovery capabilities to additional therapeutic programs.

View Septerna Profile